IX:NYSEORIX Corporation Analysis
Data as of 2026-05-25 - not real-time
$38.85
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
ORIX shares are trading well above the 20‑day, 50‑day and 200‑day moving averages, confirming a strong bullish trend. The MACD line sits comfortably above its signal line, while the RSI has climbed into overbought territory, indicating momentum that could sustain near‑term upside. Current price sits just below the recent resistance level, with a solid support cushion well above the 30‑day low, and volume has remained stable despite a 38% 30‑day volatility. The computed beta near unity suggests market‑aligned price movement, and the discounted cash‑flow model points to a modest upside of roughly 5 %.
Fundamentally, the company posted a record net income for the fiscal year ended March 2026 and raised its profit target, driven by asset disposals and accelerated cash returns. A forward P/E of just over three versus an industry average of 16.8 signals significant undervaluation, while the trailing P/E sits comfortably below peers. The dividend yield of 2.58% is backed by a low 22% payout ratio and a balance sheet with cash far exceeding total debt, despite a high debt‑to‑equity ratio. Management’s guidance and recent news of strategic divestitures reinforce a growth narrative that complements the attractive valuation and sustainable dividend profile.
Fundamentally, the company posted a record net income for the fiscal year ended March 2026 and raised its profit target, driven by asset disposals and accelerated cash returns. A forward P/E of just over three versus an industry average of 16.8 signals significant undervaluation, while the trailing P/E sits comfortably below peers. The dividend yield of 2.58% is backed by a low 22% payout ratio and a balance sheet with cash far exceeding total debt, despite a high debt‑to‑equity ratio. Management’s guidance and recent news of strategic divestitures reinforce a growth narrative that complements the attractive valuation and sustainable dividend profile.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Price near short‑term resistance with overbought RSI
- Strong bullish technical alignment (MACD, SMAs)
- Stable volume and moderate volatility
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Record earnings and upward profit guidance
- Significant valuation gap (forward P/E ~3)
- Sustainable dividend and net‑cash position
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Diversified global financial operations reducing concentration risk
- Continued asset disposals and cash returns boosting ROE
- Undervalued relative to peers with upside potential
Key Metrics & Analysis
Financial Health
Revenue Growth28.00%
Profit Margin13.43%
P/E Ratio15.5
ROE10.42%
ROA2.40%
Debt/Equity141.40
P/B Ratio1.5
Op. Cash Flow$1369.6B
Free Cash Flow$-1643793743872
Industry P/E16.8
Technical Analysis
TrendBullish
RSI71.7
Support$31.48
Resistance$39.38
MA 20$35.36
MA 50$32.44
MA 200$29.30
MACDBullish
VolumeStable
Fear & Greed Index91.61
Valuation
Fair Value$25,963.42
Target Price$38.87
Upside/Downside0.06%
GradeUndervalued
TypeBlend
Dividend Yield2.58%
Risk Assessment
Beta1.00
Volatility38.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.